ArticleBioinformatics and biology insights2026
Systems Vaccinology-Integrated Proteomics to Develop a Novel Prophylactic and Therapeutic Vaccine Against Human Papillomavirus 16.
Article in Bioinformatics and biology insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a major global health burden, with high-risk human papillomavirus (HPV), particularly HPV-16, responsible for most cases. While licensed prophylactic HPV vaccines are effective, their type-restricted coverage and lack of therapeutic activity highlight the need for next-generation vaccine strategies. In this study, a systems vaccinology-based approach was used to design a multi-epitope vaccine with both prophylactic and therapeutic potential against HPV-16. Immunodominant epitopes eliciting immune responses from HPV-16 E5, E6, E7, and L2 proteins were identified using immunoinformatics methods. Transcriptomic and pathway enrichment analysis of cervical cancer data sets identified interleukin-17A (IL-17A) signaling as a favorable immune axis, supporting its inclusion as a cytokine adjuvant. Population coverage evaluation demonstrated broad global applicability, with a predicted coverage of 99.98% across MHC class I and II alleles. Among 7 designed constructs, 1 candidate (model D) exhibited favorable physicochemical and structural properties, including high predicted solubility (73%), strong model quality, and antigenic potential. Docking analyses indicated strong correlations between native complexes and the corresponding vaccine-IL-17 receptor A and C complexes (Pearson
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.